LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

544.56 -1.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

543

Max

553.81

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-89M 275M
Pardavimai	-8.7M 782M
P/E Sektoriaus vid.	21.006 50.102
Pelnas, tenkantis vienai akcijai	5.82
Pelno marža	35.176
Darbuotojai	1,400
EBITDA	-176M 348M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+17.96% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-537M 24B
Ankstesnė atidarymo kaina	546.15
Ankstesnė uždarymo kaina	544.56

Naujienos nuotaikos

By Acuity

25%

75%

20 / 344 reitingas Healthcare

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-01 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

2026-06-01 23:38; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

2026-06-01 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Dexus Stuck in 'Too Hard' Basket -- Market Talk

2026-06-01 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

2026-06-01 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Greg Abel's Week Is Off to Quite a Start -- WSJ

2026-06-01 21:53; UTC

Rinkos pokalbiai

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

2026-06-01 21:22; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-01 20:46; UTC

Įsigijimai, susijungimai, perėmimai

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

2026-06-01 20:22; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares $11 Special Div

2026-06-01 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

2026-06-01 19:40; UTC

Rinkos pokalbiai

Remittances to Mexico Rise for Third Straight Month -- Market Talk

2026-06-01 19:28; UTC

Rinkos pokalbiai

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

2026-06-01 19:01; UTC

Rinkos pokalbiai

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

2026-06-01 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

2026-06-01 18:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

2026-06-01 18:33; UTC

Rinkos pokalbiai

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

2026-06-01 18:32; UTC

Rinkos pokalbiai

Precious Metals Fall to Start June -- Market Talk

2026-06-01 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 17:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

17.96% į viršų

12 mėnesių prognozė

Vidutinis 656.85 USD 17.96%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

20 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.